Survodutide, a Dual Glucagon-GLP-1 Agonist, Achieves Up to 14.9% Weight Loss in Phase 2 Obesity Trial

This was a randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial conducted at 43 centers across 12 countries. Participants aged 18–75 with BMI ≥27 kg/m² and without diabetes were randomly assigned (1:1:1:1:1, stratified by sex) to receive weekly subcutaneous survodutide at 0.6, 2.4, 3.6, or 4.8 mg, or placebo for 46 weeks (20 weeks dose escalation, 26 weeks dose maintenance). The primary endpoint was percentage change in body weight from baseline to week 46. The trial was funded by Boehringer Ingelheim.

The obesity drug landscape has been dominated by GLP-1 receptor agonists like semaglutide, but dual agonists that also activate the glucagon receptor could offer additional weight loss by increasing the body's energy expenditure on top of appetite suppression. Survodutide's 14.9% weight loss is competitive with other leading obesity drugs and establishes dual agonism as a viable therapeutic strategy. This trial laid the groundwork for Phase 3 studies that could lead to FDA approval.

Survodutide is part of a rapidly evolving next generation of peptide-based obesity drugs. While semaglutide (Wegovy) targets only GLP-1, and tirzepatide (Mounjaro/Zepbound) targets GLP-1 and GIP, survodutide targets GLP-1 and glucagon — a different dual mechanism. The glucagon component is thought to boost energy expenditure and improve liver fat metabolism. Multiple pharmaceutical companies are racing to develop multi-receptor peptide agonists, and this trial positions Boehringer Ingelheim's survodutide as a serious contender in what has become one of the most competitive therapeutic markets in medicine.

As a Phase 2 dose-finding trial, the study was not powered for definitive efficacy conclusions. The 40% dropout rate over 46 weeks is notable, though similar to other obesity drug trials. Gastrointestinal side effects were frequent, and long-term safety beyond 46 weeks is unknown. The study excluded people with diabetes, so efficacy and safety in diabetic obesity populations is not established. The trial was funded by the drug manufacturer (Boehringer Ingelheim).